Late hepatic allograft dysfunction

Liver Transplantation

Volumn 7, Issue 11 SUPPL. 1, 2001, Pages s60-s73

  Wiesner, Russell H ^a   Narayanan Menon, K V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; ERYTHROMYCIN; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERFERON; KETOCONAZOLE; LAMIVUDINE; MACROLIDE; RIBAVIRIN;

ALLOGRAFT; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; BILIARY CIRRHOSIS; BILIARY TRACT DISEASE; BOLUS INJECTION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MONITORING; NONHUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RADIODIAGNOSIS; RECIPIENT; RECURRENT DISEASE; SCREENING TEST; VASCULAR DISEASE;

EID: 0035184350     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.29094     Document Type: Article

References (98)

1. Adult living donor liver transplantation: Preferences about donation outside the medical community
2. Diagnosis and treatment of hepatic allograft dysfunction
3. Trends in expenditures for medicare liver transplant recipients
4. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome
5. Timing, significance, and prognosis of late acute liver allograft rejection
6. Allograft rejection after liver transplantation for autoimmune liver disease
7. Underlying disease as a predictor for rejection after liver transplantation
8. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group
9. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus
10. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation
11. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection J
12. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1048 liver transplantations with a mean follow-up of 6 years
13. Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection
14. Analysis of the reversibility of chronic liver allograft rejection-implications for a staging schema
15. Update on the International Banff schema for liver allograft rejection: Working recommendations for the histopathological staging and reporting of chronic rejection. Meeting Report
16. Hepatic artery thrombosis after orthotopic liver transplantation: A review of nonsurgical causes
17. Delayed hepatic artery thrombosis in adult orthotopic liver transplantation-A 12-year experience
18. An analysis of late hepatic artery thrombosis after orthotopic liver transplant
19. Hepatic artery stenosis after liver transplantation-Incidence, presentation, treatment, and long term outcome
20. Complications of venous reconstruction in human orthotopic liver transplantation
21. Ascites after liver transplantation
22. Liver transplantation: Late complications of the biliary tract and their management
23. Biliary complications of reduced-organ liver transplantation
24. The predictive value of transabdominal ultrasonography in the diagnosis of biliary tract complications after orthotopic liver transplantation
25. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation
26. Endoscopic management of biliary strictures in liver transplant recipients: Effect on patient and graft survival
27. Long-term efficacy of endoscopic stenting in patients with stricture of the biliary anastomosis after orthotopic liver transplantation
28. Results of choledochojejunostomy in the treatment of biliary complications after liver transplantation in the era of nonsurgical therapies
29. Hepatitis C virus infection
30. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
31. Predictors of patient and graft survival following liver transplantation for hepatitis C
32. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury
33. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation
34. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation
35. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation
36. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus DNA in liver transplant recipients: Relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection
37. Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation
38. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin
39. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study
40. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin
41. Liver transplantation in European patients with the hepatitis B surface antigen
42. Hepatitis B immune globulin to patient infection following liver transplantation: A concise review
43. High pre-treatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
44. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
45. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
46. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
47. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
48. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients
49. Adefovir dipivoxil for the treatment of lamivudine resistant hepatitis B mutants
50. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
51. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis
52. Histologic evidence for recurrence of primary biliary cirrhosis after liver transplantation
53. Recurrence of primary biliary cirrhosis in the liver allograft: The effect of immunosuppression
54. Late recurrent post-transplant primary biliary cirrhosis in British Columbia
55. Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow-up study
56. Recurrence of primary biliary cirrhosis in the liver allograft: The effect of immunosuppression
57. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection?
58. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: Evidence of recurrent disease
59. Fibrous and obliterative cholangitis in liver allografts: Evidence of recurrent primary sclerosing cholangitis?
60. Clinicopathologic findings of recurrent primary sclerosing cholangitis after orthotopic liver transplantation
61. Biliary strictures in hepatic transplants: Prevalence and types in patients with primary sclerosing cholangitis vs those with other liver diseases
62. Recurrence of primary sclerosing cholangitis following liver transplantation
63. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: Is chronic rejection part of the disease process?
64. Liver transplantation for autoimmune hepatitis: A long-term pathologic study
65. Liver transplantation for autoimmune hepatitis
66. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis
67. Recurrent autoimmune hepatitis after orthotopic liver transplantation
68. Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease
69. Recurrent autoimmune hepatitis after liver transplantation: Diagnostic criteria, risk factors, and outcome
70. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient
71. Recurrence of nonalcoholic steatohepatitis after liver transplantation
72. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation
73. Recurrence of nonalcoholic steatohepatitis following liver transplantation
74. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis
75. Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: A systematic review
76. Long-term infectious complications of liver transplantation
77. Infections in solid-organ transplant recipients
78. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation
79. Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation
80. Infections with cytomegalovirus and other herpes viruses in 121 liver transplant recipients: Transmission by donated organs and the effect of OKT3 antibodies
81. Cytomegalovirus hepatitis in liver transplantation: Prospective analysis of 93 consecutive orthotopic liver transplantation
82. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
83. Prevention of cytomegalovirus disease in recipients of solid-organ transplants
84. Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: An in situ hybridization study
85. Epstein-Barr virus hepatitis after liver transplantation
86. Epstein-Barr virus infection in liver transplantation patients: Correlation of histopathology and semiquantitative Epstein-Barr virus-DNA recovery using polymerase chain reaction
87. Posttransplant lymphoproliferative disorder in liver allograft biopsies: A comparison of three methods for the demonstration of Epstein-Barr virus
88. Epstein-Barr virus related localized hepatic lymphoproliferative disorders after liver transplantation
89. Epstein-Barr virus induced posttransplant lymphoproliferative disorders
90. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen
91. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy
92. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis
93. Rising incidence of hepatocellular carcinoma in the United States
94. Liver transplantation of small hepatocellular carcinoma in patients with cirrhosis
95. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
96. Commonly used drugs and drug interaction
97. Long-term issues in liver transplantation